Date de publication
Géographie
Langue de la ressource
Texte disponible en version intégrale
Open Access / OK to Reproduce
Évalué par des pairs
L’objectif
Despite benefits, discontinuation is common, with half of patients discontinuing in the first year of treatment. Addressing OUD is a major clinical priority, yet little is known about the causes of medication discontinuation from the patient perspective.
Constatations/points à retenir
Qualitative analysis identified the following themes relating to discontinuation: health system barriers (eg, logistical hurdles, rules and policy violations), medication effects (adverse effects; attributed adverse effects, lack of efficacy in treating chronic pain) and desire for opioid use. Patient description of decisions to discontinue buprenorphine could be multicausal, reflecting provider or system-level barriers in interaction with patient complexity or medication ambivalence.
La conception ou méthodologie de recherche
Qualitative interviews (n=20)
